tanimilast: Clinical Trials

1 trial of tanimilast, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 terminated. 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 31Terminated 1

Follow tanimilast: new trials by email Literature Review of tanimilast trials Research Report on tanimilast

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
CHF6001 1600µg, CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease
Phase 3TerminatedChiesi Farmaceutici S.p.A.39732021-07-122026-02-02

Conditions studied

Bronchitis, Chronic (1)  ·  Pulmonary Disease, Chronic Obstructive (1)

Sponsors

Chiesi Farmaceutici S.p.A. (1)

Countries

Argentina (1)  ·  Austria (1)  ·  Bosnia and Herzegovina (1)  ·  Bulgaria (1)  ·  Chile (1)  ·  Croatia (1)  ·  Czechia (1)  ·  Estonia (1)  ·  Germany (1)  ·  Greece (1)  ·  Hungary (1)  ·  Israel (1)  ·  Latvia (1)  ·  Mexico (1)  ·  Netherlands (1)

NIH funding

2023 (1)